A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042

Status: Open to Accrual

Learn more:

• clinicaltrials.gov: #NCT03393845
• See Study Locations on Big Ten CRC Website

Study Contact: studies@hoosiercancer.org; (317) 921-2050.